electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium

Core Insights - electroCore, Inc. announced that its product gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium, effective October 1, 2025 [1][2] - The reimbursement policy allows coverage for gammaCore Sapphire to treat patients with cluster headaches, based on strong clinical evidence supporting its efficacy and cost-effectiveness, thus ensuring broader access for Belgian patients [2][3] Company and Product Details - electroCore is a commercial-stage bioelectronic medicine and wellness company focused on improving health through innovative non-invasive technologies, with gammaCore and Quell neurostimulator as its leading products [5] - The company emphasizes the significance of securing long-term reimbursement in Belgium as a major milestone for expanding access to its non-invasive therapies [4] Partnerships and Market Expansion - Silvert Medical, electroCore's distribution partner in Belgium, played a crucial role in securing the reimbursement by leveraging local expertise and provider relationships, and is committed to extending access to gammaCore in neighboring countries [3][4] - The partnership with Silvert Medical is highlighted as a key factor in bringing gammaCore to patients in Belgium and enhancing the company's market presence in Europe [4]